Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Researchers report 'promising' ASF vaccine breakthrough
The vaccine was created by deleting a series of genes from the ASF virus.

Chinese teams develop ‘safe and effective’ vaccine

Researchers from China’s Harbin Veterinary Institute have reported that an African Swine Fever (ASF) vaccine has been developed which has proved safe and effective under laboratory testing.

In a research paper published in Science China Life Sciences, the research team stated that the live vaccine was created by deleting a series of genes from the virus using the country’s first ASF strain as a backbone.

The researchers said: “We used the Chinese ASFV HLJ/18 as a backbone to generate six viruses bearing different gene deletions, and found that HLJ/18-7GD, which has seven genes deleted, is fully attenuated in pigs, has a low risk of converting to a virulent strain, and could induce solid protection in pigs against lethal ASFV challenge.

“HLJ/-18-7GD has been fully evaluated and proven to be safe and effective against ASFV. We therefore expect that this vaccine will play an important role in the control of ASFV.”

Safety evaluations showed that, after intramuscular injection, the HLJ/18-7GD virus did not appear in the blood or any other organs, and only remained in the lymph nodes of pigs for a short period. From this, researchers surmised that HLJ/18-7GD is “highly unlikely to convert to a virulent strain during its replication in pigs.”

Testing also found that the vaccine tested safely in pregnant sows and did not cause abortion when administered in the early, middle and late stages of pregnancy, nor limit the rate of piglets born.

Development of the vaccine was overseen by the Chinese Academy of Agricultural Sciences. At present, there has been no estimate given as to when it could be put into production.

Become a member or log in to add this story to your CPD history

BSAVA partners with BVA Live 2026

News Story 1
 BSAVA is to partner with BVA Live (11-12 June 2026) to champion clinical research.

The organisation will be supporting BVA Live's Clinical Abstracts programme, showcasing selected abstracts of veterinary research throughout the event.

The clinical abstracts can be on any small animal veterinary subject, and must be based on research undertaken in industry, practice or academia. Abstracts can be presented in poster or oral formats.

Submissions will open on 15th December 2025, and close on 6th March 2026. You can register interest here

Click here for more...
News Shorts
Nominations open for RCVS and VN Council elections

The nomination period for the 2026 RCVS Council and VN Council elections is now open, with three veterinary surgeon seats and two veterinary nurse seats available.

Prospective candidates can download an information pack and nomination form from the RCVS website. Individuals can nominate themselves for the elections, with the results to be announced in the spring.

Clare Paget, the recently appointed RCVS Registrar and elections returning officer, said: "If you want to play your part in influencing and moulding how the professions are regulated, and making key decisions on matters of great importance to your peers, the public and animal health and welfare, please consider standing for RCVS Council or VN Council next year."

Nominations close at 5pm on Saturday, 31 January 2026.